New drug combo targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-phase study tests a new drug called ASKC202, given alone or with another drug (ASK120067), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. A…
Phase: PHASE1 • Sponsor: Jiangsu Aosaikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC